1. Home
  2. Southern Africa
  3. South Africa
  • News

Local firm loses government AIDS drug tender

South African generic drug manufacturer Thembalami Pharmaceuticals is out of the running in the government's anti-AIDS drug tender.

Thembalami, a joint venture between the leading local drug firm, Adcock Ingram, and India's Ranbaxy, was until recently one of three generic drug producers on a short list of nine that included drug giants GlaxoSmithKline and Boehringer Ingelheim.

Ranbaxy's withdrawal of four antiretroviral drugs from the South African market last week meant Thembalami automatically fell out of the tendering process.

The planned rollout of antiretroviral drugs in South Africa is the biggest in the world, making its drug tender a lucrative prize for the chosen drug manufacturer.


This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions

Share this article

Our ability to deliver compelling, field-based reporting on humanitarian crises rests on a few key principles: deep expertise, an unwavering commitment to amplifying affected voices, and a belief in the power of independent journalism to drive real change.

We need your help to sustain and expand our work. Your donation will support our unique approach to journalism, helping fund everything from field-based investigations to the innovative storytelling that ensures marginalised voices are heard.

Please consider joining our membership programme. Together, we can continue to make a meaningful impact on how the world responds to crises.

Become a member of The New Humanitarian

Support our journalism and become more involved in our community. Help us deliver informative, accessible, independent journalism that you can trust and provides accountability to the millions of people affected by crises worldwide.

Join